Congratulations to Beijing Allgens bionic mineralized collagen products as an international original included in the "innovative medical device product catalog (2018)"

In order to further implement the Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry (No. 11 [2016] of the State Council), increase the publicity of innovative medical device products, and promote the sustainable and healthy development of the pharmaceutical industry, with the joint support of the Ministry of Industry and Information Technology, the National Health Commission, the State Food and Drug Administration and other relevant departments, on December 5, 2018, the Ministry of Science and Technology announced 87 innovative medical device products and entered the "Innovative Medical Device Product Catalog (2018)". Among them, the bionic mineralized collagen artificial bone repair material of Beijing Allgens Pharmaceutical Technology Co., Ltd. was included as one of the few "international original" projects in the catalog.

Allgens Pharmaceutical's impressive performance today is inseparable from the common struggle of the corporate team over the years. As early as 2004, Professor Cui Fuzhai, doctoral supervisor of the School of Materials Science and Technology of Tsinghua University and director of the Institute of Regenerative Medicine and Biomimetic Materials, established Beijing Allgens Pharmaceutical Technology Co., Ltd. with his elite research team. Based on the research results of mineralized collagen bionic bone materials for more than 30 years, Professor Cui Fuzhai has successfully developed the "mineralized collagen artificial bone repair material" product with independent intellectual property rights after years of pioneering and innovation. Once the product has been promoted, it has been well received by many academic journals in the industry (including SCIENCE and NATURE).

The company's bionic mineralized collagen bone repair medical device products have now obtained three Chinese CFDA Class III medical device registration certificates in the fields of orthopedics, stomatology and neurosurgery, and obtained the US FDA medical device product registration certificate in 2015. Products in China and the United States clinical use of more than one million cases, bone regeneration repair effect is good.

Today, on the 40th anniversary of reform and opening up, the flower of Allgens Group has taken advantage of the spring breeze of "deepening reform" and opened all over the country to establish the "Allgens International Health Industrial Park" in Weifang, Shandong ". And in response to the call of "Belt and Road Initiative", it has set up subsidiaries overseas and sold its products to all parts of the world, realizing an important step in Allgens international strategy and striving for the grand blueprint of "establishing a multinational high-tech enterprise headquartered in China!

"Endeavour in a new era of orthopedics, striding forward in a new journey of orthopedics, and creating a new future in orthopedics", all employees of Allgens Company will uphold this concept, be brave in pioneering, keep forging ahead, and strive to become the first person in the field of artificial bone in China.